Looking at revenue growth geographically, compared to last year, first quarter net sales in the U.S. increased 2%, while internationally, we grew an impressive 11%. In Europe, we were up 6% on a constant-currency basis. Japan had a particularly strong quarter, growing 19%, which included some benefit from a competitor's quality issue in stents that John Weiland will address a little later. Our other international businesses grew 15% in constant currency, driven by a 29% growth in our emerging markets.On the business development front, we don't have any new deals coming up at this time, but I can tell you that the transactions we closed in the fourth quarter last year are proceeding as planned. We told you that we had expected ClearStream and Medivance together to contribute about 200 basis points of growth this year, and that was their impact on the first quarter. Later, you'll hear John DeFord's update at the LEVANT 2 trial from the Lutonix acquisition continues its rapid enrollment and is going according to our plans.
CR Bard's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.